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Introduction {#sec001}
============

*Plasmodium knowlesi* is a monkey malaria parasite that infects humans and causes significant mortality and morbidity in endemic areas. This parasite is transmitted via the bite of the *Anopheles* mosquito of the Leucosphyrus group. Following the discovery of a large number of human *P*. *knowlesi* infections in Sarawak, Borneo Malaysia in 2004 \[[@pone.0222681.ref001]\], similar infections have been reported in all countries in Southeast Asia, the China-Myanmar border and the Andaman and Nicobar islands in the Indian Ocean \[[@pone.0222681.ref002]--[@pone.0222681.ref005]\]. In Malaysia, *P*. *knowlesi* has replaced *Plasmodium vivax* as the main cause of human malaria infections in the country with 3164 cases in 2017 most of which occur in Malaysian Borneo \[[@pone.0222681.ref006]\].

Malaria as an infectious disease is generally recognized as one of the factors that contributes to variability in the human Duffy blood group system. The Duffy blood group was first described by Cutbush in 1950 through the discovery of an antibody in a multitransfused hemophiliac patient \[[@pone.0222681.ref007]\]. This antibody was reactive with an antigen, denoted as Fy^a^. An allelic variant of the antigen, Fy^b^, was identified a year later \[[@pone.0222681.ref008]\]. The Duffy antigens occur on the surface of erythrocytes and are encoded by the *DARC* (Duffy antigen receptor for chemokines) gene located on the long arm of chromosome 1 (1.q22-1.q23) \[[@pone.0222681.ref009]\]. This gene has two major codominant alleles, *FY\*A* and *FY\*B* which differ from each other by a missense mutation in the major cDNA transcript (G125A\>Gly42Asp) \[[@pone.0222681.ref010]\]. A third allele, *FY\*B*^*es*^, is a result of a substitution at the GATA box motif of the FY\*B promoter (-33 T\>C) \[[@pone.0222681.ref011]\]. This mutation results in the disruption at the binding site of the GATA-1 erythroid transcription factor which in turn results in the loss of FY expression in the erythroid lineage. These alleles confer the common Duffy phenotypes Fy(a+b+), Fy(a+b-), Fy(a-b+) and Fy(a-b-).

The geographical distribution of the Duffy alleles differ between regions with the *FY\*A* allele having high frequencies in many Asian populations, while the *FY\*B* allele is found predominately in European populations. This differs in most of the African regions where the *FY\*B*^*es*^ is the dominant allele \[[@pone.0222681.ref012]\]. The DARC is a receptor for chemokines and plays a crucial role in the regulation of circulating chemokine levels \[[@pone.0222681.ref013]\]. Studies have associated Duffy polymorphisms with resistance or susceptibility to disease \[[@pone.0222681.ref014]\] and the absence of the Duffy blood group to lower neutrophil count \[[@pone.0222681.ref015]\]. The DARC also plays a critical function for the entry of *P*. *vivax* and *P*. *knowlesi* into human erythrocytes. Erythrocytes of the Fy(a-b-) phenotype are found to be refractory to invasion by these merozoites \[[@pone.0222681.ref016]--[@pone.0222681.ref018]\].

Our previous study outlined the Duffy allele frequencies, genotypes and phenotypes of *P*. *knowlesi* infected patients and healthy donors from Peninsular Malaysia, in which a dominant *FY\*A* allelic and *FY\*A/FY\*A* genotypic distribution (\>89%) was observed \[[@pone.0222681.ref019]\]. However, to date there is no data on the distribution of the Duffy blood group in Malaysian Borneo. Interestingly, it has been observed that the Malaysian Borneo has more cases of *P*. knowlesi infection and more occurrences of hyperparasitemia or severe cases compared to Peninsular Malaysia \[[@pone.0222681.ref020]--[@pone.0222681.ref022]\]. The reason for these increased occurrences are currently unknown. Thus, the current study aims to identify the frequency distribution of the Duffy alleles and genotypes in Malaysian Borneo and determine if a particular Duffy genotype confers increased susceptibility to *P*. *knowlesi* infection.

Materials and methods {#sec002}
=====================

Blood samples and sample collection {#sec003}
-----------------------------------

*P*. *knowlesi* patient blood samples (n = 79) were collected from clinics in Malaysian Borneo states including the Sabah and Sarawak states from 2012 to 2018. Symptomatic patient blood samples were confirmed for *P*. *knowlesi* infection via microscopic examination of thick and thin smears and PCR based on the *Plasmodium* small subunit ribosomal RNA genes \[[@pone.0222681.ref001], [@pone.0222681.ref023]\]. Blood samples from a control group of healthy donors (n = 76) were also collected from Malaysian Borneo and included in the study. These healthy donors had been diagnosed as malaria negative by PCR and had no previous malarial infections. A total of 120 Sarawak and 35 Sabah samples were obtained via convenience sampling for the purposes of this study. To minimize participation bias, only patients that were symptomatic for malaria were invited to participate in this study. Samples were collected from various districts hospitals in the Sabah and Sarawak state of Malaysia instead of a single sampling site to ensure that the samples are representative of a large geographic region of Malaysian Borneo. Furthermore, it should be noted that Malaysian Borneo is ethnically diverse which includes native indigenous groups, Chinese, and Malays. Thus, for the purpose of this study, only the indigenous native blood samples were used to ensure that the results of the genotyping study were a true representation of the Duffy distribution in the native Malaysian Borneo population.

Ethical approval for this study was obtained from the University of Malaya Medical Centre Ethic Committee (MEC Ref. No. 817.18) and informed written or verbal consent from the donor or the next of kin was obtained for use of these samples in diagnosis. Verbal consent was used to obtain patient consent if the participant was found to be illiterate and unable to give written consent. This consent procedure was approved by the University of Malaya Medical Centre Ethic Committee.

Genomic DNA extraction and allele-specific PCR (ASP-PCR) {#sec004}
--------------------------------------------------------

Genomic DNA was extracted from blood samples using a commercial blood extraction kit according to the manufacturer's protocol (QIAGEN, Hilden, Germany). Allele specific-PCR was used to determine the Duffy blood group genotypes based on four sets of primers as previously described \[[@pone.0222681.ref019]\]. Briefly, each genomic DNA sample was subjected to three different PCR reactions to amplify the *FY\*A*, *FY\*B* and *FY\*B*^*es*^ gene respectively using a combination of the four primers mentioned. Two of these PCR reactions used the *FY* forward primer paired with either the *FY\*A* or *FY\*B* specific reverse primer. The third reaction used a combination of a forward primer that annealed to the mutated promoter region of the *FY\*B*^*es*^ and the *FY\*B* specific reverse primer. The expected size for the PCR product was 713 base pairs in length.

PCR conditions that were previously optimized were used to amplify the Duffy alleles \[[@pone.0222681.ref019]\]. The PCR reaction was set up in a 20 μl reaction with 0.5 μg of genomic DNA, 0.4 μM of forward and reverse primer, 0.2 μmM of dNTP, 2 mM MgCl~2~ and 1 unit of Taq DNA polymerase in the appropriate buffer (Promega, WI, U.S.A.). PCR conditions were initiated with an initial denaturation of one cycle at 94 °C for 2 minutes followed by 30 cycles of 30 seconds at 94 °C, 1 minute at 60 °C for annealing and 1 minute at 72 °C performed in a Biorad MyCycler thermal cycler (Biorad, CA, U.S.A.). All PCR reactions were terminated after a 10 minute extension at 72 °C and PCR products were analyzed by gel electrophoresis on a 2% agarose gel stained with SYBR Safe DNA gel stain (Invitrogen, OR, U.S.A.).

*P*. *knowlesi* culture {#sec005}
-----------------------

Human-adapted *P*. *knowlesi* A1-H1 strain (a kind gift from Robert W. Moon, London School of Hygiene and Tropical Medicine, London, UK) was maintained with fresh human erythrocytes in RPMI-1640- based medium (Invitrogen Life Technologies, NY, U.S.A.) and *P*. *knowlesi* schizonts were purified as previously described \[[@pone.0222681.ref024]\].

*P*. *knowlesi* invasion assay {#sec006}
------------------------------

Purified schizont preparations were mixed separately with *FY\*AB/ FY\*A* and *FY\*A/ FY\*A* Duffy genotype blood such that the starting schizont parasitemia was no more than 12%. The respective mixture was then diluted to 4% haematocrit using complete RPMI-1640 media. Aliquots of 100μl of each mixture were then distributed into 96-well plates and gassed with 90% N~2~, 5% O~2~, and 5% CO~2~. The cultures were then incubated at 37°C for an average of 15 hours, depending on the stage of parasite maturation to allow for parasite re-invasion to occur. Technical replicates were prepared for both the *FY\*AB/ FY\*A* and *FY\*A/ FY\*A* blood cultures. Thin blood smears were made at the end of the incubation period when newly invaded ring-stage parasites were found. The number of rings/trophozoite in 4000 erythrocytes was counted to determine the mean invasion percentage.

Statistical analysis {#sec007}
--------------------

Gene frequencies were calculated by the gene-counting method. Fisher's exact test was used to evaluate the significance of the genotypic and allelic variables and to assess the independence among the proportions of Duffy genotype alleles in *P*. *knowlesi* infected patients and blood donors. The independent non-parametric Mann-Whitney test was used to determine the differences between the means of the *FY\*AB/ FY\*A* and *FY\*A/ FY\*A* in the *P*. *knowlesi* invasion assay with 95% CI (GraphPad Prism Ver. 5.01). A two-tailed P-value equal to or less than 0.05 was considered statistically significant.

Results {#sec008}
=======

A total of 155 blood samples were genotyped, 76 of which were from healthy donors and 79 from *P*. *knowlesi* infected patients. The proportion of Duffy genotype frequencies between healthy donors and *P*. *knowlesi* positive samples is summarized in [Table 1](#pone.0222681.t001){ref-type="table"}. The results show almost equal distribution between the homozygous *FY\*A/FY\*A* and heterozygous *FY\*A/FY\*B* genotypes. Healthy donors have 45% and 55% genotype distribution and *P*. *knowlesi* positive samples with 53% and 47% distribution respectively. This is reflected in the proportion of predicted phenotypes for both groups, with the Fy (a+b-) and Fy (a+b+) phenotypes occurring at similar frequencies of 49% and 50% respectively ([Table 2](#pone.0222681.t002){ref-type="table"}). There were no significant differences between the frequencies of either the *FY\*A/FY\*A* or *FY\*A/FY\*B* genotypes between healthy donors or *P*. *knowlesi* patient samples. The homozygous *FY\*B/FY\*B* genotype and corresponding Fy (a-b+) phenotype was only observed in one individual from the healthy donor group. No Duffy negative genotype (*FY\*B*^*ES*^*/FY\*B*^*ES*^) or Fy (a-b-) phenotype was detected.

10.1371/journal.pone.0222681.t001

###### Comparison of genotypic frequencies between blood donors and *P*. *knowlesi* infected patients.

![](pone.0222681.t001){#pone.0222681.t001g}

  Genotypes                                     Donors (n = 76)   Patients *P*. *knowlesi* (n = 79)   P-value
  --------------------------------------------- ----------------- ----------------------------------- ---------
  ***FY\*A/FY\*B***                             41 (55%)          37 (47%)                            0.423
  ***FY\*A/FY\*A***                             34 (45%)          42 (53%)                            0.336
  ***FY\*A/FY\*B***^***ES***^                   0                 0                                   
  ***FY\*B/FY\*B***                             1(1%)             0                                   0.490
  ***FY\*B/FY\*B***^***ES***^                   0                 0                                   
  ***FY\*B***^***ES***^***/FY\*B***^***ES***^   0                 0                                   

10.1371/journal.pone.0222681.t002

###### Proportion of predicted phenotypes of blood donors and *P*. *knowlesi* infected patients.

![](pone.0222681.t002){#pone.0222681.t002g}

  Predicted phenotype   No. of individuals
  --------------------- --------------------
  **Fy (a+b+)**         78 (50%)
  **Fy (a+b-)**         76 (49%)
  **Fy (a-b+)**         1 (1%)
  **Fy (a-b-)**         0

As for allelic distribution ([Table 3](#pone.0222681.t003){ref-type="table"}), the *FY\*A* was found to be the predominant allele in both groups, with a frequency of 0.717 in healthy donors and 0.766 in *P*. *knowlesi* patient samples. The *FY\*B* allele had allelic frequency of 0.283 and 0.234 in healthy donors and *P*. *knowlesi* patients respectively. The *FY\*B*^*ES*^ allele was not detected in either group. The distribution of the *FY\*A* and *FY\*B* alleles was not significantly different (P = 0.728, P = 0.531) between the healthy donor and *P*. *knowlesi* samples.

10.1371/journal.pone.0222681.t003

###### Comparison of allelic frequencies between blood donors and *P*. *knowlesi* infected patients.

![](pone.0222681.t003){#pone.0222681.t003g}

  Alleles                 Donors (n = 76)   Patients *P*. *knowlesi* (n = 79)   P-value
  ----------------------- ----------------- ----------------------------------- ---------
  ***FY\*A***             0.717 (72%)       0.766 (77%)                         0.728
  ***FY\*B***             0.283 (28%)       0.234 (23%)                         0.531
  ***FY\*B***^***ES***^   0                 0                                   

To further study the susceptibility of the two predominant Duffy genotypes (*FY\*AB/ FY\*A* and *FY\*A/ FY\*A*) to *P*. *knowlesi* invasion, an *in vitro* invasion assay was conducted. The mean percent invasion for *FY\*AB/ FY\*A* and *FY\*A/ FY\*A* were 10.48% and 9.753% respectively ([Table 4](#pone.0222681.t004){ref-type="table"}). Statistical analysis shows that there was no significant difference between the mean percent invasion for both Duffy blood genotypes ([Fig 1](#pone.0222681.g001){ref-type="fig"}) indicating that neither blood group has increased susceptibility to *P*. *knowlesi* infection.

10.1371/journal.pone.0222681.t004

###### Comparison of invasion percentage between the Duffy *FY\*AB* and *FY\*A* blood group.

![](pone.0222681.t004){#pone.0222681.t004g}

                          *FY\*AB/ FY\*A* percent invasion (%) ± SD   *FY\*A/ FY\*A* percent invasion (%) ± SD   P-value
  ----------------------- ------------------------------------------- ------------------------------------------ ---------
  Replicate 1             11.57                                       9.45                                       
  Replicate 2             10.86                                       10.64                                      
  Replicate 3             9.00                                        9.17                                       
  Mean percent invasion   10.48±1.33                                  9.75±0.78                                  0.700

![Mean percent invasion of *P*. *knowlesi* in *FY\*AB/ FY\*A* and *FY\*A/ FY\*A* Duffy blood groups.\
Data shown was the mean percent invasion with standard deviation in each group. The difference between *FY\*A/FY\*A* or *FY\*A/FY\*B* genotypes was not significantly different. \**P*\<0.05.](pone.0222681.g001){#pone.0222681.g001}

Discussion {#sec009}
==========

The Duffy blood group system has been widely used for population differentiation and ethnic composition studies. It has also been a popular chromosomal marker for evaluating the impact of natural selection in different geographical locations \[[@pone.0222681.ref025], [@pone.0222681.ref026]\]. The Duffy blood group also has an important role in transfusion medicine \[[@pone.0222681.ref027], [@pone.0222681.ref028]\], and invasion of *P*. *vivax* and *P*. *knowlesi* into erythrocytes \[[@pone.0222681.ref016], [@pone.0222681.ref017]\]. In the present study we looked at the distribution of the Duffy blood group in Malaysian Borneo and determined its possible role in susceptibility to *P*. *knowlesi* infection.

The Duffy blood group distribution is well studied and characterized, with the *FY\*A* allele being the most abundant globally \[[@pone.0222681.ref012]\]. This allele clusters primarily in the Asian continent, Australia and eastern parts of Russia. The *FY\*B* allele on the other hand is found to cluster primarily in the European continent and in pockets of the Americas and its frequency decreases eastwards towards the Asia. The *FY\*B*^*ES*^ allele on the other hand is found to be primarily distributed in the African region where it has reached fixation across parts of west, central, and east Africa. The allelic frequencies of 30 countries across Africa were found to be \>90% *FY\*B*^*ES*^ \[[@pone.0222681.ref012]\].

Our previous study on the Duffy blood group in Peninsular Malaysia was in agreement with this trend, indicating an overwhelmingly *FY\*A* dominant distribution with allelic frequencies of 0.937 (94%) and *FY\*A/FY\*A* being the dominant genotype at 89.2% \[[@pone.0222681.ref019]\]. This allelic and genotypic distribution was similar to those of neighbouring countries such as Thailand \[[@pone.0222681.ref029], [@pone.0222681.ref030]\], Indonesia (Bugis, Toraja, and Irian Jaya area) \[[@pone.0222681.ref031]\], Philippines \[[@pone.0222681.ref032]\], Taiwan \[[@pone.0222681.ref032]\], and China \[[@pone.0222681.ref033], [@pone.0222681.ref034]\]. With our previous study on the Duffy genotypes in Peninsular Malaysia in mind, we sought to determine if similar distributions were observed in Malaysian Borneo or if the distributions would differ due to the geographic separation of the Borneo island. To that end we collected new samples from a cohort of Malaysian Borneo *P*. *knowlesi* infected patients and healthy donors. We found that the data on the Duffy genotypes in Malaysian Borneo markedly contrast with that of the data of the Duffy genotypes in Peninsular Malaysia from our previous study and those of the neighbouring regions, with the almost similar distribution of the *FY\*AB/ FY\*A* and *FY\*A/ FY\*A* at 50% and 49% respectively. Furthermore, the allelic distributions were 0.724 (74.2%) and 0.252 (25.2%) for the *FY\*A* and *FY\*B* allele respectively. This is particularly interesting as the countries that geographically surround Malaysian Borneo i.e. Peninsular Malaysia, Indonesia, and the Philippines are predominantly of the *FY\*A/FY\*A* genotype (\>80%). This also differs greatly from the global distribution of the Duffy genotypes in which mainland Asian and Southeast Asian regions show *FY\*A* allele dominance \[[@pone.0222681.ref012], [@pone.0222681.ref035]\].

Admixture of *FY\*A* and *FY*\*B in a population may be due to movement of migrants globally over time as can be seen in the evolution of Duffy genotypes in North America and the Americas with migrations from the European continent and early migration from Asian population \[[@pone.0222681.ref035]\]. Similarly, the admixture of the *FY\*B*^*ES*^ allele seen in Brazil and other regions in the Americas were noted in individuals with African ancestry \[[@pone.0222681.ref036]\]. This however does not seem to be the case in our findings as the surrounding regions around Malaysian Borneo are of a predominantly *FY\*A/FY\*A* genotype thus population movement would not explain the high incidence of *FY\*A/FY\*B* genotypes. Furthermore, the target population sampled for this study was of native indigenous Borneo ancestry without any admixture of other ethnicities indicating that this distribution is unlikely to be due to admixture with other populations in or around the region. There is currently no studies available on the Duffy allele distribution in Brunei or the Kalimantan region of Indonesia, thus it is unknown if the Duffy allele distribution of the entire Borneo island is similarly distributed.

Following the discovery of this pocket of *FY\*A/FY\*AB* in a predominantly *FY\*A/FY\*A* region, we decided to investigate if either genotype confers an increased susceptibility to *P*. *knowlesi* infection. Previous studies have shown that the *P*. *vivax* Duffy Binding Protein-II (PvDBPII), a receptor that facilitates invasion, has significantly lower binding to the Fy^a^ antigen compared to Fy^b^. Furthermore, King *et al* found that Fy^a^ was associated with protection but Fy^b^ was associated with increased infection and disease \[[@pone.0222681.ref035]\]. A study by Miller *et al* suggested that *P*. *knowlesi* had a lower efficiency in infecting human Fy^a+b-^ compared to Fy^a-b+^ \[[@pone.0222681.ref017]\]. Similarly, *in vitro* invasion studies of *P*. *knowlesi* have shown a reduced efficiency of invasion for Fy (a+b-) erythrocytes compared to Fy(a-b+) erythrocytes \[[@pone.0222681.ref037]\]. These prior studies indicate that the *FY\*A* allele confers some resistance to infection and conversely *FY\*B* is associated with increased susceptibility to *P*. *knowlesi* invasion. A previous study on *P*. *knowlesi* Duffy Binding Protein II (PkDBPαII) found that this protein showed different binding activity between Malaysian Peninsular and Borneo erythrocytes \[[@pone.0222681.ref038]\]. Further studies showed that the PkDBPαII protein had a higher binding activity to Fy (a+b+) compared to Fy (a+b-) erythrocytes \[[@pone.0222681.ref039]\].

However, our analysis of the mean percent invasion of FY\*AB/ FY\*A and FY\*A/ FY\*A erythrocytes showed no significant difference in invasion rates between these two genotypes. Although a prior study by Miller *et al* \[[@pone.0222681.ref017]\] observed a marked reduction in *P*. *knowlesi* invasion of Fy (a+b-) erythrocytes compared to Fy (a-b+) it should be noted that this was done via an invasion inhibition assay using Duffy positive erythrocytes coated with anti-Fy^a^ and anti- Fy^b^ antiserum and may not accurately mimic natural *P*. *knowlesi* invasion into different Duffy genotype erythrocytes. Indeed, in the same paper the authors also carried out an invasion assay using different duffy genotype erythrocytes and noted that the invasion rates for three Duffy positive genotypes, Fy (a+b-+), Fy (a-b+), and Fy (a+b+) were similar which is consistent with our findings. Our previous study also found that the binding activity of PkDBPαII was higher in Fy (a+b+) compared to Fy (a+b-) erythrocytes. However, binding efficiency and rosette formation are not currently linked to *P*. *knowlesi* invasion into human RBC's, thus binding efficiency may not always be concordant with *P*. *knowlesi* invasion rates.

In *P*. *vivax* endemic areas such as Iran \[[@pone.0222681.ref040]\], where the frequency of Fy (a+b-) was 11% higher in vivax patients compared to healthy donors; India \[[@pone.0222681.ref041]\], where the prevalence of Duffy Fy (a+b-) was 83.3% in malaria patients compared to (59.0%) healthy participants; and Brazil \[[@pone.0222681.ref042]\], where Fy (a+b-) was found to be significantly higher in *P*. *vivax* patients (34.93%) compared to healthy donors (27.27%); it was noted that the Duffy Fy (a+b-) carried higher susceptibility for *P*. *vivax* infection. Thus, the question arose if the Duffy genotypes played a similar role in increasing susceptibility to *P*. *knowlesi* infection. The results of our genotyping however show that there is no significant difference in the distribution of *FY\*AB/ FY\*A* and *FY\*A/ FY\*A* between *P*. *knowlesi* infected patient samples and healthy donors. This indicates that neither the *FY\*AB/ FY\*A* nor the *FY\*A/ FY\*A* genotype confers any differences in susceptibility to *P*, *knowlesi* infection. We further studied this *in vitro* via an invasion assay and the results of the assay were concordant with our genotyping results where it was observed that there was no significant difference between the mean percent invasion of *FY\*AB/ FY\*A* and *FY\*A/ FY\*A* erythrocytes. Thus, unlike *P*. *vivax*, *P*. *knowlesi* infects erythrocytes indiscriminately regardless of *FY\*A* or *FY*\*B genotype.

Conducting an invasion inhibition assay using anti- Fy^a^ and anti- Fy^b^ antibodies to block a combination of these specific antigens on human erythrocytes would allow for a more robust investigation of *P*. *knowlesi* invasion rates between different Duffy genotypes. However, this does come at the expense of observing natural *P*. *knowlesi* invasion rates in invasion assay using different Duffy genotype erythrocytes. Ideally, conducting invasion assays using different Duffy genotype erythrocytes in comparison with invasion inhibition assays using anti- Fy^a^ and anti- Fy^b^ antibodies would allow for a more comprehensive analysis of the *P*. *knowlesi* invasion rates between the different Duffy genotypes and is a future study that merits investigation. Another limitation of the study is the lack of complete sociodemographic data, thus we chose to omit this data from the study. Ideally, our future studies on Borneo genotyping will include complete patient data to study the influence of sociodemographic factors on knowlesi susceptibility.

Conclusion {#sec010}
----------

This is a first report on the Duffy blood group distribution in Malaysian Borneo and the first effort at studying the difference in *P*. *knowlesi* invasion between Duffy Fy (a+b+) and Fy (a+b-) erythrocytes. Our results revealed an interesting cluster of the *FY*\**A*/*FY*\*B genotype in Malaysian Borneo which is in stark contrast to surrounding regions and global expected Duffy blood group distributions. Our results have also shown that there is no significant difference in susceptibility to *P*. *knowlesi* infection between the *FY\*A/FY\*A* and *FY\*A/FY\*B* genotype. Further studies into the Duffy distribution in the Kalimantan region of Indonesia and in Brunei would help define if this *FY\*A/FY\**B distribution is observed throughout the entire Borneo island thus providing merit for further investigation into the cause of this unique admixture of Duffy alleles in this geographic region.
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